In vitro and in vivo binding of (E)- and (Z)-N-(iodoallyl)spiperone to dopamine D2 and serotonin 5-HT2 neuroreceptors

John R. Lever, Ursula A. Scheffel, Marigo Stathis, John L. Musachio, Henry N. Wagner

Research output: Contribution to journalArticle

Abstract

Apparent affinities (Ki) of (E)- and (Z)-N-(iodoallyl)spiperone ((E)- and (Z)-NIASP) for dopamine D2 and serotonin 5-HT2 receptors were determined in competition binding assays. (Z)-NIASP (Ki 0.35 nM, D2; Ki 1.75 nM, 5-HT2) proved slightly more potent and selective for D2 sites in vitro than (E)-NIASP (Ki 0.72 nM, D2; Ki 1.14 nM, 5-HT2). In vivo, radioiodinated (E)- and (Z)-[125I]-NIASP showed regional distributions in mouse brain which are consonant with prolonged binding to dopamine D2 receptors accompanied by a minor serotonergic component of shorter duration. Stereoselective, dose-dependent blockade of (E)-[125I]-NIASP uptake was found for drugs binding to dopamine D2 sites, while drugs selective for serotonin 5-HT2, α1- adrenergic and dopamine D1 receptors did not inhibit radioligand binding 2 hr postinjection. Specific binding in striatal tissue was essentially irreversible over the time course of the study, and (E)-[125I]-NIASP gave a striatal to cerebellar tissue radioactivity concentration of 16.9 to 1 at 6 hr postinjection. Thus, (E)-[125I]-NIASP binds with high selectivity and specificity to dopamine D2 sites in vivo.

Original languageEnglish (US)
Pages (from-to)1967-1976
Number of pages10
JournalLife Sciences
Volume46
Issue number26
DOIs
StatePublished - 1990

Fingerprint

Sensory Receptor Cells
Dopamine
Serotonin
Corpus Striatum
Serotonin 5-HT2 Receptors
Tissue
Dopamine D1 Receptors
Serotonin Agents
Dopamine D2 Receptors
In Vitro Techniques
N-(iodoallyl)spiperone
Radioactivity
Pharmaceutical Preparations
Adrenergic Agents
Assays
Brain

ASJC Scopus subject areas

  • Pharmacology

Cite this

In vitro and in vivo binding of (E)- and (Z)-N-(iodoallyl)spiperone to dopamine D2 and serotonin 5-HT2 neuroreceptors. / Lever, John R.; Scheffel, Ursula A.; Stathis, Marigo; Musachio, John L.; Wagner, Henry N.

In: Life Sciences, Vol. 46, No. 26, 1990, p. 1967-1976.

Research output: Contribution to journalArticle

Lever, John R. ; Scheffel, Ursula A. ; Stathis, Marigo ; Musachio, John L. ; Wagner, Henry N. / In vitro and in vivo binding of (E)- and (Z)-N-(iodoallyl)spiperone to dopamine D2 and serotonin 5-HT2 neuroreceptors. In: Life Sciences. 1990 ; Vol. 46, No. 26. pp. 1967-1976.
@article{be7ae2f2c704487bb0c39c1a3075470c,
title = "In vitro and in vivo binding of (E)- and (Z)-N-(iodoallyl)spiperone to dopamine D2 and serotonin 5-HT2 neuroreceptors",
abstract = "Apparent affinities (Ki) of (E)- and (Z)-N-(iodoallyl)spiperone ((E)- and (Z)-NIASP) for dopamine D2 and serotonin 5-HT2 receptors were determined in competition binding assays. (Z)-NIASP (Ki 0.35 nM, D2; Ki 1.75 nM, 5-HT2) proved slightly more potent and selective for D2 sites in vitro than (E)-NIASP (Ki 0.72 nM, D2; Ki 1.14 nM, 5-HT2). In vivo, radioiodinated (E)- and (Z)-[125I]-NIASP showed regional distributions in mouse brain which are consonant with prolonged binding to dopamine D2 receptors accompanied by a minor serotonergic component of shorter duration. Stereoselective, dose-dependent blockade of (E)-[125I]-NIASP uptake was found for drugs binding to dopamine D2 sites, while drugs selective for serotonin 5-HT2, α1- adrenergic and dopamine D1 receptors did not inhibit radioligand binding 2 hr postinjection. Specific binding in striatal tissue was essentially irreversible over the time course of the study, and (E)-[125I]-NIASP gave a striatal to cerebellar tissue radioactivity concentration of 16.9 to 1 at 6 hr postinjection. Thus, (E)-[125I]-NIASP binds with high selectivity and specificity to dopamine D2 sites in vivo.",
author = "Lever, {John R.} and Scheffel, {Ursula A.} and Marigo Stathis and Musachio, {John L.} and Wagner, {Henry N.}",
year = "1990",
doi = "10.1016/0024-3205(90)90513-Q",
language = "English (US)",
volume = "46",
pages = "1967--1976",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "26",

}

TY - JOUR

T1 - In vitro and in vivo binding of (E)- and (Z)-N-(iodoallyl)spiperone to dopamine D2 and serotonin 5-HT2 neuroreceptors

AU - Lever, John R.

AU - Scheffel, Ursula A.

AU - Stathis, Marigo

AU - Musachio, John L.

AU - Wagner, Henry N.

PY - 1990

Y1 - 1990

N2 - Apparent affinities (Ki) of (E)- and (Z)-N-(iodoallyl)spiperone ((E)- and (Z)-NIASP) for dopamine D2 and serotonin 5-HT2 receptors were determined in competition binding assays. (Z)-NIASP (Ki 0.35 nM, D2; Ki 1.75 nM, 5-HT2) proved slightly more potent and selective for D2 sites in vitro than (E)-NIASP (Ki 0.72 nM, D2; Ki 1.14 nM, 5-HT2). In vivo, radioiodinated (E)- and (Z)-[125I]-NIASP showed regional distributions in mouse brain which are consonant with prolonged binding to dopamine D2 receptors accompanied by a minor serotonergic component of shorter duration. Stereoselective, dose-dependent blockade of (E)-[125I]-NIASP uptake was found for drugs binding to dopamine D2 sites, while drugs selective for serotonin 5-HT2, α1- adrenergic and dopamine D1 receptors did not inhibit radioligand binding 2 hr postinjection. Specific binding in striatal tissue was essentially irreversible over the time course of the study, and (E)-[125I]-NIASP gave a striatal to cerebellar tissue radioactivity concentration of 16.9 to 1 at 6 hr postinjection. Thus, (E)-[125I]-NIASP binds with high selectivity and specificity to dopamine D2 sites in vivo.

AB - Apparent affinities (Ki) of (E)- and (Z)-N-(iodoallyl)spiperone ((E)- and (Z)-NIASP) for dopamine D2 and serotonin 5-HT2 receptors were determined in competition binding assays. (Z)-NIASP (Ki 0.35 nM, D2; Ki 1.75 nM, 5-HT2) proved slightly more potent and selective for D2 sites in vitro than (E)-NIASP (Ki 0.72 nM, D2; Ki 1.14 nM, 5-HT2). In vivo, radioiodinated (E)- and (Z)-[125I]-NIASP showed regional distributions in mouse brain which are consonant with prolonged binding to dopamine D2 receptors accompanied by a minor serotonergic component of shorter duration. Stereoselective, dose-dependent blockade of (E)-[125I]-NIASP uptake was found for drugs binding to dopamine D2 sites, while drugs selective for serotonin 5-HT2, α1- adrenergic and dopamine D1 receptors did not inhibit radioligand binding 2 hr postinjection. Specific binding in striatal tissue was essentially irreversible over the time course of the study, and (E)-[125I]-NIASP gave a striatal to cerebellar tissue radioactivity concentration of 16.9 to 1 at 6 hr postinjection. Thus, (E)-[125I]-NIASP binds with high selectivity and specificity to dopamine D2 sites in vivo.

UR - http://www.scopus.com/inward/record.url?scp=0025285404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025285404&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(90)90513-Q

DO - 10.1016/0024-3205(90)90513-Q

M3 - Article

C2 - 2362552

AN - SCOPUS:0025285404

VL - 46

SP - 1967

EP - 1976

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 26

ER -